Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.43 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3850987 | 0.90 | HDAC6 (0.45) | FGFR1SLC22A6HPRT1NT5EPNP | |
| SCHEMBL3859183 | 0.88 | CDK1 (0.49) | FGFR1SLC22A6CDK1CCNB1CCNE1 | |
| SCHEMBL3859201 | 0.88 | CDK1 (0.49) | FGFR1SLC22A6CDK1CCNB1CCNE1 | |
| SCHEMBL3861102 | 0.83 | POLB (0.61) | NT5EPOLB | |
| SCHEMBL3856920 | 0.82 | CCNE1 (0.48) | FGFR1SLC22A6CDK1CCNB1CCNE1 | |
| SCHEMBL3857906 | 0.81 | HPRT1 (0.66) | HPRT1PNPPOLB | |
| Pmedap SCHEMBL215611 | 0.81 | FGFR1 (0.72) | FGFR1SLC22A6CDK1CCNB1CCNE1 | |
| Pmedap SCHEMBL29571667 | 0.81 | FGFR1 (0.72) | FGFR1SLC22A6CDK1CCNB1CCNE1 | |
| SCHEMBL6005006 | 0.81 | CDK1 (0.46) | CDK1CCNB1CCNE1CDK2ENPP1 | |
| SCHEMBL3850956 | 0.80 | CYP3A4 (0.52) | FGFR1SLC22A6CDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885CDK1 359/4885 |
| US-20140206675-A1 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, BACE2, APP | FGFR1 1934/4885SLC22A6 4681/4885CDK1 124/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | FGFR1 3686/4885SLC22A6 1014/4885CDK1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.